Healthcare organizations are increasingly piloting clinical AI tools, but a common challenge emerges quickly: when is there enough signal to act?
In most cases, organizations are working with limited data, short evaluation periods, and mixed or incomplete signals. Waiting for definitive evidence is often not practical. At the same time, acting too quickly can introduce risk.
The goal is not certainty. The goal is informed judgment based on early signals.
What Early Evaluation Produces
Early-stage evaluation, using a Minimum Viable Evaluation approach, is not designed to produce definitive evidence. Instead, it produces directional signals across a small number of KPIs, early insight into workflow fit and user experience, and initial indications of value through directional ROI.
These signals are often sufficient to support a practical decision when interpreted together.
How to Interpret Early Signals
Decisions should not be based on a single metric. They should be based on how a small number of signals align across domains.
Consistently Positive Signals: Consider Scaling
When selected KPIs are moving in a positive direction, directional ROI signals are improving, and no meaningful safety concerns have been identified, the tool may be functioning as intended and delivering value in its current context.
Mixed Signals, No Safety Concerns: Refine and Continue
When some KPIs improve while others remain neutral, or when results vary across users, workflows, or settings, the tool may still have value. However, implementation, workflow integration, or user support may need adjustment before broader scale is considered.
Limited or Unclear Signals: Reassess
When there is no consistent direction across selected KPIs, adoption is low, or directional ROI signals are unclear, the implementation may not be addressing a meaningful problem. It may also mean the evaluation period was too short to generate useful signals.
Negative Signals or Safety Concerns: Stop or Pause
When KPIs trend in the wrong direction, users consistently override or distrust the tool, or safety concerns are observed, the risks may outweigh the benefits in the current state.
What “Enough Signal” Means in Practice
In early-stage clinical AI, “enough signal” does not mean statistical significance, long-term outcome data, or complete certainty.
It typically means consistent direction across a small number of KPIs, no meaningful safety concerns, a clear understanding of how the tool is affecting workflow and user experience, and directional ROI signals that support or challenge perceived value.
This level of signal is often sufficient to support a practical decision.
Using This with the Clinical AI Toolkit
The Clinical AI Toolkit is designed to help organizations generate these signals through Minimum Viable Evaluation, selection of a small number of KPIs from the KPI Library, and directional ROI assessment.
This guide reflects how those signals can be interpreted to support decisions about whether to continue, refine, scale, or stop an AI implementation.
Key Point
Effective clinical AI adoption does not depend on perfect evidence. It depends on the ability to generate early signals, interpret them in context, and make timely, informed decisions.
Organizations that can do this consistently will move faster, learn more quickly, and scale what works.
Explore the Clinical AI Toolkit to apply this approach in practice.
Contribute to Shared Learning
Many organizations are facing similar questions as they begin evaluating clinical AI. If you have applied the Clinical AI Toolkit, consider sharing a short summary of your approach and what you observed.
We are particularly interested in what you chose to measure, what signals emerged early, and how those signals informed your decision. Contributions may be anonymized and used to develop practical examples and future guidance. Share your experience at chief@digitalhealthcanada.com.